Article: HTLV-III antibody prevalence among young delinquent drug abusers in long-term residential treatment at a North-German drug clinic

To date, long-term intravenous drug users studied at regional European centers of illicit drug use have had a high number of LAV/HTLV-III infections. Among 200 patients remanded by court or referred from prison to a special clinic in northern Germany for young delinquent drug abusers, 26 (17%) of 157 IV drug abusers were HTLV-III seropositive. With 40% seropositive, female patients showed a significantly higher prevalence of HTLV-III infection than males. The results of longitudinal serological, immunological, and clinical observations over periods of 12 months and 2-3 years indicate that under conditions of continuous medical surveillance, sound preventive counseling, and steady therapeutic care during long-term coeducative residential treatment of drug abusers, neither detectable HTLV-III transmission nor definite progression of HTLV-III induced impairment of immune regulatory functions must ensue.

Citing Articles

HIV infection in intravenous drug abusers in Berlin: risk factors and time trends.

Stark K, Muller R, Guggenmoos-Holzmann I, Deininger S, Meyer E, Bienzle U Klin Wochenschr. 1990; 68(8):415-20.

PMID: 2348645 DOI: 10.1007/BF01648583.

References

1.

Mortimer P, Vandervelde E, Jesson W, Pereira M, Burkhardt F . HTLV-III antibody in Swiss and English intravenous drug abusers. Lancet. 1985; 2(8452):449-50. DOI: 10.1016/s0140-6736(85)92771-0. View

2.

Hunsmann G, Schneider J, BAYER H, Kurth R, Werner A, Brede H . Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. Klin Wochenschr. 1985; 63(5):233-5. DOI: 10.1007/BF01731176. View

3.

Fuchs D, Blecha H, Deinhardt F, Dierich M, Goebel F, Hengster P . High frequency of HTLV-III antibodies among heterosexual intravenous drug abusers in the Austrian Tyrol. Lancet. 1985; 1(8444):1506. DOI: 10.1016/s0140-6736(85)92277-9. View

4.

Ginzburg H . Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep. 1984; 99(2):206-12. PMC: 1424536. View

5.

Angarano G, Pastore G, Monno L, Santantonio T, Luchena N, SCHIRALDI O . Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet. 1985; 2(8467):1302. DOI: 10.1016/s0140-6736(85)91581-8. View

6.

Peutherer J, Edmond E, Simmonds P, DICKSON J, Bath G . HTLV-III antibody in Edinburgh drug addicts. Lancet. 1985; 2(8464):1129-30. DOI: 10.1016/s0140-6736(85)90721-4. View

7.

Ferroni P, Geroldi D, Galli C, Zanetti A, Cargnel A . HTLV-III antibody among Italian drug addicts. Lancet. 1985; 2(8445):52-3. DOI: 10.1016/s0140-6736(85)90113-8. View

8.

Schupbach J, Vogt M, Bhushan R, Luthy R, Haller O, Joller H . [Prevalence of antibodies against HTLV-III in various regions in Switzerland]. Schweiz Med Wochenschr. 1985; 115(30):1048-54. View

9.

Curran J, Morgan W, Hardy A, Jaffe H, Darrow W, Dowdle W . The epidemiology of AIDS: current status and future prospects. Science. 1985; 229(4720):1352-7. DOI: 10.1126/science.2994217. View

10.

Joller-Jemelka H, Wilhelm U, Steffen R, Grob P . [Viral hepatitis and AIDS-associated HTLV III/LAV virus infections in drug addicts]. Schweiz Med Wochenschr. 1985; 115(33):1114-9. View

11.

Rodrigo J, Serra M, Aguilar E, del Olmo J, Gimeno V, Aparisi L . HTLV-III antibodies in drug addicts in Spain. Lancet. 1985; 2(8447):156-7. DOI: 10.1016/s0140-6736(85)90260-0. View

12.

Spira T, Des Jarlais D, Marmor M, Yancovitz S, Friedman S, Garber J . Prevalence of antibody to lymphadenopathy-associated virus among drug-detoxification patients in New York. N Engl J Med. 1984; 311(7):467-8. DOI: 10.1056/NEJM198408163110712. View

HTLV-III Antibody Prevalence Among Young Delinquent Drug Abusers in Long-term Residential Treatment at a North-German Drug Clinic